
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded vaginal gel containing ciprofloxacin hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing ciprofloxacin are listed in tablet, suspension, solution, injection and ointment forms. It is also a component of FDA-approved kits.
Gel bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Ciprofloxacin is a fluoroquinolone antibiotic that compounding pharmacies prepare as oral liquids, otic and nasal preparations and topical forms by prescription.
Ciprofloxacin is a bactericidal fluoroquinolone antibiotic. It blocks two bacterial enzymes, DNA gyrase and topoisomerase, that bacteria need to copy their DNA. It is most active against gram-negative bacteria, including Pseudomonas aeruginosa, and reaches high concentrations in urine, prostate and many tissues. Manufactured products include Cipro tablets (Bayer) and generic tablets and oral suspension, FDA-approved for bacterial infections of the urinary tract, skin, bone, abdomen, prostate and lungs, infectious diarrhea, typhoid, plague and inhalational anthrax; ophthalmic solution for corneal ulcers and conjunctivitis; and otic solution for acute otitis externa, with Cipro HC and Ciprodex adding a steroid. A prescriber might order compounded ciprofloxacin for a liquid strength or vehicle not manufactured, a nasal or otic preparation without a particular excipient, or a combination in one preparation. Compounded preparations are not FDA-approved and require a prescription.
Oral ciprofloxacin carries an FDA boxed warning: fluoroquinolones can cause disabling and potentially permanent tendinitis and tendon rupture, peripheral neuropathy, and central nervous system effects such as seizures, hallucinations or mood changes, and they can worsen myasthenia gravis. The label reserves it for patients with no other option in sinusitis, bronchitis flares and uncomplicated bladder infections. Call your prescriber right away for tendon pain, numbness, confusion, or sudden chest, stomach or back pain, which can signal an aortic tear. It can prolong the QT interval, swing blood sugar, and cause sun sensitivity, C. difficile diarrhea and liver injury. Never take it with tizanidine. It raises levels of theophylline, caffeine, clozapine and warfarin; antacids, iron, zinc, calcium and dairy block its absorption unless spaced apart. Children usually get other antibiotics because of joint effects. The label says not to breastfeed during treatment and for two days after; LactMed considers it acceptable with infant monitoring. If side effects bother you, talk to your prescriber or pharmacist.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase, with greatest potency against gram-negative bacilli and the most anti-pseudomonal activity among quinolones; resistance arises through gyrase mutation, plasmid-mediated mechanisms and efflux. Oral bioavailability is 70 to 80 percent with peak at 1 to 1.5 hours, tissue levels often exceed serum, elimination half-life is about 4 hours, 40 to 50 percent is excreted unchanged in urine by tubular secretion, and 20 to 35 percent is recovered in feces. It inhibits CYP1A2. Labeled indications span Cipro and generic oral forms (UTI, skin, bone and joint, complicated intra-abdominal, lower respiratory, sinusitis, prostatitis, infectious diarrhea, typhoid, gonorrhea, plague, post-exposure anthrax; pediatric use limited to complicated UTI, plague and anthrax), ophthalmic solution, and otic solution and suspension products. StatPearls lists off-label oral use in Crohn's disease with perianal fistula. Compounded otic, nasal and topical preparations are prepared in the strength and vehicle the prescriber specifies. Monitoring: tendon symptoms, mental status, blood glucose in patients on antidiabetics, QT interval with interacting drugs or electrolyte disturbance, CBC and renal and hepatic function during prolonged therapy, INR with warfarin and theophylline levels. Advise hydration to limit crystalluria and sun avoidance for phototoxicity. Not a controlled substance.
Wash your hands. Fill the applicator to the mark on your label, or use a prefilled applicator. Lie on your back with knees bent, insert the applicator gently as far as is comfortable, and push the plunger slowly until it stops. Remove the applicator; wash a reusable one with mild soap and water or discard a single-use one. Bedtime use is common. Wash your hands afterward.
A gel can have a nonaqueous or a water-based base, and USP <795> sets its default beyond-use date by water content, not by the word gel. A nonaqueous gel usually carries a beyond-use date of up to 180 days at room temperature or refrigerated. A water-based gel carries up to 35 days with a preservative, or 14 days refrigerated without one. Your label states which applies. Keep the container closed, keep from freezing, keep out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Insert/apply intravaginally